Overview
Parnax Lab Limited, formerly Krishna Deep Trade & Investment Ltd, was incorporated in 1982 and is engaged in manufacturing and exporting pharmaceutical formulations.
Naxpar Pharma Private Limited, a subsidiary, has over two decades of expertise in pharmaceuticals and is acclaimed for innovation in cosmetics, herbal formulations, and nutraceuticals.
The company is recognized for its high-quality manufacturing standards, holding ISO 9002 certification from RWTUV, Germany, for its good quality systems.
Naxpar's competitive manufacturing edge includes state-of-the-art facilities located in Silvassa and Baddi, serving a diverse international clientele.
Strategically, Naxpar is poised for expansion into South East Asia, CIS, and LatAm, leveraging its WHO approval and compliance with international EHS standards.
- Sector
Pharmaceuticals & Biotechnology
- Industry
Pharmaceuticals
- Market Cap
146 Cr
- Volatility
Moderate Risk
- P/E Ratio
12.4
- Industry P/E
34.1
- PEG Ratio
0.3
- P/B Ratio
1.5
- 52W High
182.00
- 52W Low
96.25
Financial Ratios
Sales CAGR
- 1Y
- -0.51%
- 3Y
- -0.61%
- 5Y
- -1.78%
- 10Y
- -0.38%
Profit CAGR
- 1Y
- 19.96%
- 3Y
- 37.07%
- 5Y
- —
- 10Y
- —
ROE
- TTM
- 12.38%
- 3Y
- 13.70%
- 5Y
- 12.62%
- 10Y
- 9.87%
ROCE
- TTM
- 12.15%
- 3Y
- 18.29%
- 5Y
- 18.23%
- 10Y
- 16.49%
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
